# Compugen (stock symbol: CGEN) Logo in transparent PNG and SVG formats

## Compugen Logo large

### Compugen Logo large Download PNG (17.43 KB)

![Compugen Logo large Download PNG (17.43 KB)](/img/orig/CGEN_BIG-f080e768.png)

### Compugen Logo large Download SVG (7.88 KB)

![Compugen Logo large Download SVG (7.88 KB)](/img/orig/CGEN_BIG-3d249b84.svg)

## Compugen Logo icon format

### Compugen Logo icon format Download PNG (19.29 KB)

![Compugen Logo icon format Download PNG (19.29 KB)](/img/orig/CGEN-e1c35d43.png)

### Compugen Logo icon format Download SVG (3.07 KB)

![Compugen Logo icon format Download SVG (3.07 KB)](/img/orig/CGEN-85e54e11.svg)

## Compugen Logo large for dark backgrounds

### Compugen Logo large for dark backgrounds Download PNG (17.43 KB)

![Compugen Logo large for dark backgrounds Download PNG (17.43 KB)](/img/orig/CGEN_BIG.D-9084ee41.png)

### Compugen Logo large for dark backgrounds Download SVG (7.88 KB)

![Compugen Logo large for dark backgrounds Download SVG (7.88 KB)](/img/orig/CGEN_BIG.D-3e87bea2.svg)

## Compugen Logo icon format for dark backgrounds

### Compugen Logo icon format for dark backgrounds Download PNG (19.29 KB)

![Compugen Logo icon format for dark backgrounds Download PNG (19.29 KB)](/img/orig/CGEN.D-8341babf.png)

### Compugen Logo icon format for dark backgrounds Download SVG (3.07 KB)

![Compugen Logo icon format for dark backgrounds Download SVG (3.07 KB)](/img/orig/CGEN.D-1136791b.svg)

## About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

1. Website domain: cgen.com
2. Employees: 73
3. Marketcap: $51.1 Million USD


## Categories
- [x] üáÆüá± Israel
- [x] üë®‚Äçüíª Software
- [x] üë©‚Äçüíª Tech
- [x] üß¨ Biotech
